Results 131 to 140 of about 351,949 (320)

Dental fluorosis in the European roe deer (Capreolus capreolus): A review of the pathological changes in the enamel of fluorotic cheek teeth and the abnormal pattern of dental wear in affected dentitions

open access: yesThe Anatomical Record, EarlyView.
Abstract This article reviews the pathological changes in the enamel of permanent mandibular cheek teeth and their sequelae in European roe deer from regions polluted by anthropogenic fluoride emissions. The primary (developmental) changes of fluorotic roe deer enamel are hypomineralization and microstructural aberrations, including enamel hypoplasia ...
Uwe Kierdorf, Horst Kierdorf
wiley   +1 more source

Genomic Insights Into a Strong Biofilm‐Forming Enterococcus faecalis MTR_EFS01 Strain Isolated From a Shrimp in Bangladesh

open access: yesAnimal Research and One Health, EarlyView.
This study characterizes a multidrug‐resistant and strong biofilm‐forming Enterococcus faecalis strain obtained from a shrimp sample in Bangladesh. ABSTRACT Enterococcus faecalis is known for its ability to form strong biofilms and its role as an opportunistic pathogen. In this study, we screened and characterized a multidrug‐resistant (MDR) and strong
Md. Ashek Ullah   +4 more
wiley   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera   +14 more
wiley   +1 more source

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis

open access: yesArthritis &Rheumatology, EarlyView.
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley   +1 more source

Home - About - Disclaimer - Privacy